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Biological macromolecules including DNA, RNA, and proteins, have intrinsic features that make
IP
:
them potential building blocks for the128.46.220.88
bottom-up fabrication of nanodevices. RNA is unique in
27 Nov
2007of13:01:57
nanoscale fabrication due to Tue,
its amazing
diversity
function and structure. RNA molecules can be

designed and manipulated with a level of simplicity characteristic of DNA while possessing versatility
in structure and function similar to that of proteins. RNA molecules typically contain a large variety
of single stranded loops suitable for inter- and intra-molecular interaction. These loops can serve
as mounting dovetails obviating the need for external linking dowels in fabrication and assembly.
The self-assembly of nanoparticles from RNA involves cooperative interaction of individual RNA
molecules that spontaneously assemble in a predeﬁned manner to form a larger two- or threedimensional structure. Within the realm of self-assembly there are two main categories, namely
template and non-template. Template assembly involves interaction of RNA molecules under the
inﬂuence of speciﬁc external sequence, forces, or spatial constraints such as RNA transcription, hybridization, replication, annealing, molding, or replicas. In contrast, non-template assembly
involves formation of a larger structure by individual components without the inﬂuence of external
forces. Examples of non-template assembly are ligation, chemical conjugation, covalent linkage, and
loop/loop interaction of RNA, especially the formation of RNA multimeric complexes. The best characterized RNA multiplier and the ﬁrst to be described in RNA nanotechnological application is the
motor pRNA of bacteriophage phi29 which form dimers, trimers, and hexamers, via hand-in-hand
interaction. phi29 pRNA can be redesigned to form a variety of structures and shapes including
twins, tetramers, rods, triangles, and 3D arrays several microns in size via interaction of programmed
helical regions and loops. 3D RNA array formation requires a deﬁned nucleotide number for twisting
and a palindromic sequence. Such arrays are unusually stable and resistant to a wide range of
temperatures, salt concentrations, and pH. Both the therapeutic siRNA or ribozyme and a receptorbinding RNA aptamer or other ligands have been engineered into individual pRNAs. Individual
chimeric RNA building blocks harboring siRNA or other therapeutic molecules have been fabricated
subsequently into a trimer through hand-in-hand interaction of the engineered right and left interlocking RNA loops. The incubation of these particles containing the receptor-binding aptamer or
other ligands results in the binding and co-entry of trivalent therapeutic particles into cells. Such
particles were subsequently shown to modulate the apoptosis of cancer cells in both cell cultures
and animal trials. The use of such antigen-free 20–40 nm particles holds promise for the repeated
long-term treatment of chronic diseases. Other potentially useful RNA molecules that form multimers include HIV RNA that contain kissing loop to form dimers, tecto-RNA that forms a “jigsaw
puzzle,” and the Drosophila bicoid mRNA that forms multimers via “hand-by-arm” interactions.
Applications of RNA molecules involving replication, molding, embossing, and other related techniques, have recently been described that allow the utilization of a variety of materials to enhance
diversity and resolution of nanomaterials. It should eventually be possible to adapt RNA to facilitate
construction of ordered, patterned, or pre-programmed arrays or superstructures. Given the potential for 3D fabrication, the chance to produce reversible self-assembly, and the ability of self-repair,
editing and replication, RNA self-assembly will play an increasingly signiﬁcant role in integrated
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biological nanofabrication. A random 100-nucleotide RNA library may exist in 16 × 1060 varieties
with multifarious structure to serve as a vital system for efﬁcient fabrication, with a complexity and
diversity far exceeding that of any current nanoscale system.
This review covers the basic concepts of RNA structure and function, certain methods for the
study of RNA structure, the approaches for engineering or fabricating RNA into nanoparticles or
arrays, and special features of RNA molecules that form multimers. The most recent development
in exploration of RNA nanoparticles for pathogen detection, drug/gene delivery, and therapeutic
application is also introduced in this review.
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and manipulated with both a level of simplicity characteristic of DNA41 42 and a versatile ﬂexibility in structure and function similar to that of proteins. Typically,
1. THE SUITABILITY OF RNA
RNA molecule contains large variety of single stranded
FOR NANOTECHNOLOGY
loops for inter- and/or inter-molecular interaction. These
loops can serve as mounting dovetails, thus external
The emergent ﬁeld of nanotechnology generally involves
linking dowels might not be needed in fabrication and
the characterization, manipulation, modiﬁcation, and/or
assembly.
assembly of organized materials on the nanoscale level,1 2
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RNA molecules are polymers made up of hundreds,
thousands, or millions of nucleotides from four groups:
adenosine (A), cystidine (C), guanosine (G), and uridine
(U) (see Section 3). As to a 100-nucleotide RNA polymer,
as many as 4100 (=1.6 × 1060 ) different RNA molecules
can be designed. Since the size of RNA ranges from the
angstrom to the nanometer scale, bottom-up approaches
would be reasonable for use with RNA in nanotechnological applications. The ﬁrst application in RNA nanotechnology is the construction of micrometer-scale RNA arrays
derived from the nanometer-scale building block of bacteriophage phi29 motor pRNA.43

constraint. RNA transcription, hybridization, replication,
annealing of DNA and RNA, molding, or replica, are
part of this category. Nontemplated assembly involves the
formation of a larger structure by individual components
without any inﬂuence from external forces. Included in the
nontemplated category are ligation, chemical conjugation,
covalent linkages, loop/loop interaction of RNA, and the
formation of macromolecules by structural interaction in
the formation of multimers.41 43 46–49
One of the main areas of interest in current nanotechnology is the synthesis of patterned arrays50–53 for technological applications. Arrays can be engineered to serve as chips
in the diagnosis of diseases or to function as ultrahigh
density data storage systems.21 Ordered nanocrystals have
2. GENERAL APPROACHES IN BOTTOM UP
already
been assembled into superlattices by techniques
ASSEMBLY USING RNA
such
as
colloidal crystallization,54–56 macromolecule selfAS BUILDING BLOCKS
assembly,11 57–59 complementary interactions,48 60 61 and
patterned etch pits.62 Ordered biological structural arrays
The self-assembly of nanoparticles from RNA is a promican serve as templates for the further construction of
nent bottom-up approach to obtain nanoscale, nanostrucDelivered by Ingenta
to:
superlattices.11 57 58 63 Bacteriophage phi29 pRNA has
tured materials, and thus represents an important approach
Purdue
University
Libraries
been used as building blocks for the construction of RNA
by which biological techniques and biomacromolecules
IP : 128.46.220.88
43–47
can be successfully integrated into nanotechnology.
arrays with the size in micron.43
Tue,
27
Nov
2007
13:01:57
Such approaches rely upon the cooperative interaction of
Various applications involving replication, molding,
individual RNA molecules that spontaneously assemble
embossing, and other related techniques have recently been
in a predeﬁned manner to form a larger two- or threeemerging,45 allowing for the utilization of a variety of
dimensional structure. Within the realm of self-assembly
materials to improve the diversity and to enhance the reshere are two main subcategories: templated assembly and
olution of nanomaterials. It may eventually be possible
nontemplated assembly. Templated assembly involves the
to speciﬁcally adapt RNA for use in many of these techinteraction of RNA with one another under the inﬂuniques, which would facilitate the construction of ordered,
ence of a speciﬁc external force, structure, or spatial
patterned or preprogrammed arrays or superstructures. It is
Dr. Guo is a Professor of Molecular Virology and Biomedical Engineering at Purdue University where he serves as the Director of the Lab of Gene Therapy. His research expertise
lies in viral DNA packaging and RNA biochemistry. He has been working on bottom-up
assembly of biomacromolecules in nanoscale for more than twenty years. For example, he
constructed an in-vitro phi29 DNA packaging motor (the most powerful biomotor studied to
date) (PNAS, 1986); discovered the motor pRNA (the viral RNA that binds ATP) (Science,
1987); and served as the guest editor of the Journal Viral Assembly in 1994. However,
he has not used the word “nanotechnology” until recently. Other pioneering work includes
his demonstration that RNA can serve as building blocks for the construction of devices
in nanotechnology. His latest contribution is the application of RNA nanotechnology for
gene or drug delivery to treat cancers and viral-related diseases and for pathogen detection.
His lab is the ﬁrst to assemble infectious dsDNA virions in the test tube using synthetic components and puriﬁed
recombinant nanomotors. His ﬁnding that pRNA binds ATP and forms a hexamer to gear the phi29 DNA-packaging
motor suggests that RNA might play a role that protein enzymes (such as helicase) play. His research effort has led
to an NIH “First Award” in 1992, the “Pﬁzer Distinguished Faculty Award for Research Excellence” in 1995, the
“Purdue Faculty Scholar” in 1998, and the “Seed Award” in 2004. Dr. Guo came to the United States at the end of
1983. He ﬁnished his Ph.D. training in Microbiology and Genetics in Dr. Dwight Anderson’s lab at the University of
Minnesota/School of Dentistry in May of 1987. He was a postdoctoral fellow with Dr. Enzo Paoletti in Wadsworth
Center and later a visiting scientist with Dr. Bernard Moss—a member of National Academy of Sciences at NIH. He
joined Purdue in 1990 and became a full Professor in 1997. His lab has been afﬁliated with a number of interdisciplinary
programs including Genetics, Biochemistry and Molecular Biology, Virology, the Cancer Research Center, Veterinary
Pathobiology, Nanotechnology, and Biomedical Engineering. He also founded the Purdue Graduate Program in Viral
Research. He has also chaired and been the keynote speaker at many international conferences. He is an editor or editorial
board member for six journals, including four in nanotechnology and bionanotechnology. He published 70 original
papers in high impact refereed journals including Science, PNAS, and Molecular Cell.
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evident that RNA self-assembly will play an increasingly
signiﬁcant role in integrated biological nanofabrication in
the future, given its potential for 3D fabrication, the chance
to produce reversible self-assembly, and the ability of
self-repairing and replicating. RNA serves as the ultimate
model for effective, efﬁcient nanoscale self-assembly, with
a complexity far exceeding that of any current nanoscale
systems.
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to the level of stringency; for example, a high temperature environment is likely to cause dissociation of dimer,
trimer, hexamer into monomer and any double-stranded
RNA structures into a single strand. Other conditions affect
stringency as well.
One of the RNA functions involves protein synthesis
within cells. There are a wide variety of subtypes of RNA
with different functions that have been identiﬁed. Among
the most common types are: (1) ribosomal RNA (rRNA),
which serves as the “machinery” in the process of syn3. BASIC CONCEPTS OF RNA
thesis, (2) messenger RNA (mRNA), which is responsible
STRUCTURE AND FUNCTION
for the transmission of DNA information, and (3) transfer
RNA (tRNA), which performs a variety of speciﬁc roles
Prior to a detailed description of the wide range of applications of RNA nanotechnology, it is important to provide
in protein synthesis. These and many other small RNA
some basic background information regarding RNA and
subtypes, including small interfering RNA (siRNA),64–67
its speciﬁc attributes. Following is a brief discussion of its
antisense RNA,68 69 ribozymes,70–73 aptamer RNA,74 75
process of formation and structural characteristics.
pRNA (a viral packaging RNA discussed below),76 and
Nucleotides form the basic building blocks of ribonumicroRNA,77 have potential application in nanotechnolcleic acid (RNA). These nucleic acids are composed of
ogy,Ingenta
gene therapy,
Delivered by
to: and other areas. Many of the small
three main components: (1) a base, (2) a phosphate group,
RNAs from cells and other microorganisms exhibit novel,
Purdue University Libraries
and (3) a pentose (a ﬁve-carbon sugar ribose). In chemical
emerging and/or unknown functions, and there is still
IP : 128.46.220.88
terms, the two most important differences between RNA
be learned in order to fully utilize their differing
Tue, 27 Novmuch
2007to13:01:57
and DNA are: (1) the presence of an –OH group at the
mechanisms, function, and structure.
2 position of the ribose in RNA and the absence of the
oxygen of this group in DNA (hence the deoxy—preﬁx)
4. METHODS FOR THE STUDY OF
and (2) the replacement of the uracil base (U) in RNA
RNA STRUCTURE
by the thymine base (T) in DNA. When there is only a
base/pentose composite, this structure is called “nucleoThough nucleotide derivatives have been found in RNA,
side;” when phosphate is included, a nucleotide is formed.
the primary sequence of the RNA molecule is as simple
The four nucleosides of RNA are adenosine (A), cystidine
as DNA, since both are composed of four nucleotides.
(C), guanosine (G), and uridine (U).
Both DNA and RNA can form double-helical structure, but
RNA can be synthesized chemically or enzymatically
RNA has a more diverse structure. Even the smallest RNA
by RNA polymerases. In the latter case, nucleoside
molecules, though they contain only the four nucleotides
monophosphates link the hydroxyl group of one nucleotide
A, G, C, and U, exhibit signiﬁcant versatility in biological
to the phosphate of another during transcription. A temfunction. Such versatility is ascribed to the ﬂexibility and
plate strand directs insertion of the nucleoside monophoscomplexity in RNA structural folding. NMR78–84 and X-ray
phate. In this manner, a long chain of nucleotides can be
crystallography85–89 have been used to obtain a physical
formed, with one end of the chain (the 5 end) having
tertiary structure of RNAs. Yet, the difﬁculty, uncertainty,
one or up to three phosphates and the other (the 3 end) a
and time involved in obtaining a diffractable RNA crysfree hydroxyl group. Along the length of the chain, there
tallographic structure, together with the difﬁculty of using
are two sides. One side is known as the “backbone” and
NMR for large RNAs, necessitate the use of alternative
consists of sugar and phosphate groups. The other side is
approaches to obtain information on RNA structures.
left open for the possibility of the base-pairing of chains.
This ﬂexibility allows for the construction of a wide vari4.1. Genetic Analysis by Truncation, Insertion,
ety of complex structures and provides for a considerable
Deletion, and Mutation
amount of functional diversity.
RNA will self-fold into 2D and 3D structure. A chain’s
Mutant RNAs can be easily constructed through the trunrelative level of stringency determines whether it exists in
cation, deletion, insertion, and mutation targeting of any
a double-stranded form under conditions of low stringency
desired position. For example, using an in vitro assembly
or a single-stranded form in a high stringency environassay system, dozens of mutant phi29 pRNAs can be proment. Salt concentration is generally inversely proportional
duced and tested in one to two weeks.59 90–93
to stringency, since the presence of only a small amount
of salt tends to cause the natural electrostatic repulsion
4.2. Phylogenetic Analysis
of the two strands to overcome any ionic attraction and
Phylogenetic analysis of RNA can be used to compare
thus to manifest a single-stranded, high stringency conthe sequences of RNA molecules with similar or identical
dition. In contrast, temperature is directly proportional
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functions from different species.94–97 The supposition that
RNA molecules with a similar function possess a common
secondary structure has been deduced from such analyses.
It has been found that RNA structure plays a critical role
in RNA function and that nature most often tends to select
the most stable molecule with the best-ﬁt structure or with
acceptable base co-variations. Such phylogenetic analysis
of species from nature can potentially be expanded into
molecules made artiﬁcially, such as those made by the
use of complementary modiﬁcation or SELEX (described
below).

REVIEW

4.3. SELEX

Guo

Thus this base is a possible candidate for intermolecular
interactions. A lack of modiﬁcation will most likely be due
to base pairing, especially in helical regions, but may also
be the result of tertiary interactions or non-canonical base–
base, base–sugar, or base–phosphate interactions in loop
or bulge regions.110 Such chemical modiﬁcation data can
provide information regarding base accessibility, which
is helpful in assessing and predicting secondary structures, evaluating 3-D molecular models, and analyzing
RNA/protein interactions.
Chemical modiﬁcation interference113–115 involves the
same procedure as chemical modiﬁcation; the general principle behind the interference method is that an RNA containing an interfering modiﬁed base would appear in the
fast migrating monomer band, while RNA containing a
non-interfering modiﬁed base would appear in the slower
migrating dimer band.

The SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method has permitted the identiﬁcation of unique RNA/DNA molecules from very large
populations of random sequences DNA or RNA libraries.
Usually, selections are frequently carried out with RNA
4.6. to:
Photoafﬁnity Crosslinking by Psoralen,
Delivered by Ingenta
pools due to the folding ability of RNAs into complex
GMPS/Aryl Azide, Phenphi, or Ultraviolet-Light
Purdue University Libraries
structures which can be a source of diversity of RNA
IP : 128.46.220.88
The chemical psoralen can intercalate into RNA or DNA
function.75 98–101 SELEX allows screening for co-variation
Tue, 27 Nov 2007 13:01:57
helices and after irradiation with 320–400 nm light, freeze
of several nucleotides and can be used to reveal non(in a helical or pseudoknot form) the uridines of RNA or
canonical interaction which is difﬁcult to prove by classic
the thymidines of DNA by covalent attachment116 if they
genetic and biochemical approaches.75 98–101 For example,
are in close proximity.117–120 The sites of crosslinks can
SELEX has been used to select pRNA sequences that bind
102
103
be determined by primer extension121 and/or Mung bean
procapsids and proved that pRNA can bind ATP.
nuclease treatment.122 The psoralen derivative, AMT (4 aminomethyl-4,5 ,8-trimethyl psoralen), is a good choice
4.4. Complementary Modiﬁcation
to crosslink RNA due to its solubility.121 Psoralen crosslinks only RNA or DNA but not protein, which is different
One approach often utilized to conﬁrm base-pairing in
from the azido group (see below) which crosslinks nonpredicted RNA structure is complementary modiﬁcation.
speciﬁcally to both protein and nucleic acids. Psoralen can
Before the conclusion that “G pairs to C” in an RNA
induce intra-molecular crosslinks within the RNA even in
structure can be deﬁnitively drawn, at least three mutants
the presence of other proteins and RNA conformations in
should be constructed and analyzed. These mutants, havdifferent environments can therefore be detected.
ing either one G changed to A (or U) or one C to U
Aryl azides contain functional groups that are chemi(or A) should render the mutant inactive. When both Gs
cally inert in the absence of light, but can be converted
are changed to As (or Us) and both Cs are changed to Us
to a reactive nitrene after long wavelength UV irradia(or As), the mutant should experience restored activity. For
tion which then inserts into nearby bonds resulting in
example, the complementary modiﬁcation helps the study
covalent crosslinks.123 124 Thus, aryl azides can be incorof loop/loop interaction in pRNA dimer formation.40 104 105
porated into RNA to obtain structural data.125 126 Speciﬁc internal bases of RNA can be uniquely labeled
4.5. Chemical Modiﬁcation and Chemical
with photoafﬁnity crosslinking agents to analyze interModiﬁcation Interference
and intra-molecular interactions. Crosslinked RNAs are
Chemical modiﬁcation is often employed to probe RNA
separated from uncrosslinked RNAs by denaturing gel
structure.106 107 The modifying agents utilized include
electrophoresis. Crosslink sites are determined by primer
dimethyl sulfate (DMS), which methylates A at N1, G at
extension.113 127 Bases identiﬁed as crosslink sites by
108 109
N7, and C at N3;
kethoxal, which modiﬁes G at N1
primer extension indicate that these bases are in close proxand N2;110 111 and 1-cyclohexyl-3-(2-morpholinoethyl)imity to the photoagent-labeled base. Crosslinking is used
carbodiimide metho-p-toluene sulfonate (CMCT), which
to determine the proximity in 3D structure determination.
attacks U at N3 and G at N1. The locations of modiﬁed
Unlike psoralen, phenphi [(cis-Rh(phen)(phi)Cl+
2
bases can be identiﬁed by primer extension with reverse
(phen = 1,10-phenanthroline; and phi = 9,10-phenanthrentranscriptase.108 112 The successful chemical modiﬁcation
equinone diimine)] induces covalent bonds between
of a base is a good indication that the base is unpaired
guanosine bases upon UV activation. Phenphi has also
been shown to crosslink RNA.128
and that the speciﬁc functional group is solvent-exposed.
1968
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Also, ultraviolet-induced cross-linking of RNA to protein or RNA to RNA has been proved to be an effective
methods for the study of RNA protein interaction and RNA
structure–function relationships.129
4.7. Cryo-Atomic Force Microscopy (Cryo-AFM)
Cryo-AFM130 can be performed to better elucidate the
3-D structure of RNA in native conformation.113 131 132 The
color indicates the thickness or height of the sample but
does not reﬂect the atomic density observed. The brighter
the color indicates the thicker of the sample—the darker
the color, the thinner the sample (Fig. 3).

nucleases A, T1, and V1.141 The RNA will be end-labeled,
for example, with 32 P and the optimal concentration of
enzymes is determined empirically to ensure, on the average, one cleavage site per RNA molecule. Alternatively,
the results will be analyzed by primer extension or 2D gel
analysis.
4.11. Other Methods

J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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Besides, other methods for RNA structure study are available. For example, lead (II) cleavage has previously been
used to probe tRNA structure142 and now developed
to investigate RNA structure in vivo.143 Hydroxyl radical footprinting can provide information of the solventaccessible area of a folded RNA molecule.144 Nucleotide
4.8. Computer Modeling of RNA’s
analog interference mapping make it possible to determine
Three-Dimensional Structure
the chemical basis of RNA function and structure.145 Fluorescence techniques, in particular, ﬂuorescence resonance
Once data is collected from such methods as crosslinkenergy transfer (FRET), have been employed to monitor
ing, chemical probing, chemical modiﬁcation, chemical
Delivered by
Ingenta to:
RNA conformational changes.146 147 Also, enzymatic footmodiﬁcation interference, and cryo-AFM, in addition to
Purdue
University
Libraries
printing, electrophoresis mobility shift assay (EMSA)37
other methods, computer programs can be used to effecIP
:
128.46.220.88
have been used for the studies on thermodynamics, RNA–
tively translate the data into three-dimensional consTue, 27 Novprotein
2007 13:01:57
interaction or conformational change of RNA.
tructions.133–135 Programs such as NAHELIX, MANIP,
136 137
PRENUC, NUCLIN, and NUCMULT
can be used to
model structures based on such data and constraints. Mod5. RNA MOLECULES THAT
iﬁed distance geometry and molecular mechanics algoFORM MULTIMERS
rithms using simpliﬁed “pseudo atom” representations can
be used to generate structures consistent with data from
The diverse structure and processes of the many types of
various techniques. A constraint satisfaction algorithm is
RNA play a crucial role in determining the functionalcombined with discrete representations of nucleotide conity of a variety of organisms. Understanding the speciﬁc
formations to reﬁne the disturbed area in order to ensure
attributes and conformations of these types of RNA will
the normal representation of all atoms.138
lead to advances in medicine and nanotechnology. Following are some prominent examples of different types of
RNA that form multimers by RNA–RNA interaction and
4.9. Ribonuclease Probing
their potential applications. Such interaction can be utiSome ribonucleases are speciﬁc to RNA secondary
lized for bottom-up assembly.
structure.110 122 139 For example, RNases T1 (speciﬁc for
GpN linkages), U2 (speciﬁc for ApN linkages), and S1
5.1. Motor pRNA of Bacteriophages phi29
prefer to cleave single-stranded RNA. Nuclease V1 is speA striking common feature in the maturation of all linear
ciﬁc for double stranded RNA. End-labeled RNA in var++
ds-DNA viruses is that their genome is translocated into a
ious solutions with or without containing Mg
can be
94 121
preformed protein shell.148–155 A DNA-translocating motor,
probed by T1, U2, or V1 nucleases.
T1 and V1 can be
powered by ATP hydrolysis, accomplishes this energetused to distinguish the loops and helices. In addition, T1
ically unfavorable DNA transportation process. A RNA
nuclease can be used to study changes in RNA conforma++
molecule called pRNA has been shown to have a novel and
tion. Since the activity of RNase T1 is Mg independent,
indispensable role in phi29 DNA packaging motor.76 156
this enzyme can also be used to investigate the conformapRNA contains two functional domains (Fig. 1).154 157
tional change of RNA in the presence or absence of Mg++
The procapsid binding domain is located at the central
[Ref. 121], Besides end labeling, the cleavage site can also
region91 132 141 158 bases 23–97, while the DNA translobe identiﬁed by primer extension or 2D gel analysis.
cation domain is located at the 5 /3 paired ends.104
This conclusion comes from different studies includ4.10. Footprinting
ing (a) base deletion and mutation;93 104 105 159 160 (b)
Foot printing is a technique derived from nuclease probribonuclease probing;94 121 141 159 (c) oligo targeting;161 162
ing or chemical modiﬁcation and is particularly use(d) competition assays to inhibit phage assembly;162–164
140
ful in probing the interaction of RNA with proteins.
(e) UV-crosslinking;158 (f) psoralen crosslinking;121 and
(g) primer extension.131
The procapsid/pRNA complex has been probed with
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Fig. 1. Sequence and structural elucidation of phi29 motor pRNA and
related assemblages. (A) Primary and secondary structure of wild-type
pRNA I-i . The binding domain (shaded area) and the DNA translocation
domain (the helical region) are marked with bold lines. The four bases
in the right and left loops, which are responsible for inter-RNA interactions, are boxed. (B) Three-dimensional structure of wild-type pRNA I-i
displayed as ribbon. (C) Diagrams depicting the pRNA monomer A-b
with unpaired right/left loops. (D) pRNA dimers (A-b )(B-a ). (E) pRNA
trimers (A-b )(B-e )(E-a ). (F) pRNA monomer with unpaired right/left
loops A-b and a 6-nucleotide palindromic sequence. (G) pRNA twin
A-b . (H) Size and three-dimensional computer model of phi29 pRNA
trimer. Reprinted with permission from [43], D. Shu et al., Nano Lett. 4,
1717 (2004). © 2004, American Chemical Society.

The six pRNAs form a hexagon via intermolecular
base-pairing between the right loop (bases 42–45) and
the left loop (bases 82–85).163–168 pRNA dimers are the
building blocks in hexamer assembly. pRNA has many
attributes that make it a novel choice for nanotechnological applications (Figs. 1–4). Among these are
its ATP-binding activity,103 its function in driving the
DNA-packaging motor,154 its ability to form dimers,
trimers, and hexamers,48 132 165–167 169 its tight and stable
folding,91 93 105 135 160 its two independent domains for
structure and function,104 105 141 158 and its functional similarity as compared to protein enzymes.76 154 Since the size
of RNA ranges from the angstrom to the nanometer scale,
the bottom-up approach could be reasonably applied to
RNA in nanotechnological applications. Larger RNA complexes can be constructed from the following three building blocks:
(i) Monomer with intramolecularly self-complementary
left and right loops.
(ii) Monomer with non-complementary left and right
loops for intermolecular interaction.
1970

(B)
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Monomer control
Dimer control
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Fig. 2. Polyacrylamide gel showing monomers, dimers, trimers, twins,
tetramers, and arrays. (A) Native and denatured gel. (B) Test of the stability of pRNA dimers under different conditions. Reprinted with permission
from [43], D. Shu et al., Nano Lett. 4, 1717 (2004). © 2004, American
Chemical Society.

(iii) Monomer with intermolecularly self-complementary
left and right loops and palindromic 3 ends.
5.1.1. Nomenclature of RNA Subunits
To simplify the description in the construction of RNA
complexes, uppercase and lower case letters are used to
represent the right and left hand loops of the pRNA
respectively, (Fig. 1A). The matched letters indicate
complementarity, whereas different letters indicate noncomplementary loops. For example, pRNA(A-b ) contains

right hand loop A(5 G45 G46 A47 C48 ) and left hand loop b

(3 U85 G84 C83 G82 ), which can pair with the left hand loop


a (3 C85 C84 U83 G82  and right hand loop B(5 A45 C46 G47 C48 )
respectively, of pRNA(B-a ).
5.1.2. Construction of Dimers
Dimers are formed by the intermolecular interaction of
interlocking right and left loops. Alone, the pRNAs A/b
and B/a were inactive in DNA packaging, but when mixed
together, DNA-packaging activity was restored.135 166 This
result can be explained by the trans-complementarity of
the interlocking pRNA loops, i.e., the right-hand loop A
of pRNA A/b can pair with the left-hand loop a of pRNA
B/a . Mixing two inactive pRNAs with interlocking loops,
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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Fig. 4. A mixture of two complementary twins, A-b and B-a , assembled into two distinct supramolecular structures. (A) Two complementary
twins were able to form a stable tetramer (double-twins) by assembling
into a circular structure. (B) Concatemers of alternating twins formed
when a twin interacted with two rather than one complementary twin.
Reprinted with permission from [43], D. Shu et al., Nano Lett. 4, 1717
(2004). © 2004, American Chemical Society.

5.1.3. Construction of Trimers
C. Trimer

D. Array

Fig. 3. Atomic force microscopy (AFM) showing pRNA monomers
(A), dimers (B), trimers (C), and arrays (D) of pRNA. The three insets
at the left of each panel contain images with higher magniﬁcation, as
indicated by the size of the frame. The pRNA monomers folded into a
checkmark shape, dimers displayed a rod shape, trimer exhibited triangle shape, and arrays displayed as bundles. Formation of dimers requires
Mg2+ , while the sample on mica was brieﬂy rinsed with water before
freezing for cryo-AFM, which resulted in some dissociation of dimers or
trimers even when the pRNA was already adsorbed to the activated mica
surface. The color within each image reﬂects the thickness and height of
the molecule. The brighter or whiter, the color, the thicker or taller the
molecule; the darker the image, the thinner the molecule. Reprinted with
permission from [43], D. Shu et al., Nano Lett. 4, 1717 (2004). © 2004,
American Chemical Society.
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Several sets of trimers were constructed, e.g., A-b , B-c ,
and C-a . Indeed, stable pRNA trimers are formed with a
very high efﬁciency, up to 100%, by using sets of three
interlocking pRNA.43 48 132 166 167 A mechanism similar to
that of dimer formation by interlocking loop/loop interaction is utilized to construct chimeric pRNA trimers43
carrying receptor-binding RNA aptamer and/or therapeutic RNA molecules (see below). Nucleotides 23–97 are
the central components in the formation of both dimers
and trimers. The ability to form dimers or trimers is not
affected by 5 or 3 end truncation before residue #23 and
after residue #97, since one or two truncated or extended
pRNAs can be incorporated into dimers while one, two,
or three truncated or extended pRNAs can be incorporated into trimers. Speciﬁc nucleotide assignment before
#29 and after #92 is not required for trimer formation,
as long as the complementary helix at the 3 /5 region is
generated.
Trimers are veriﬁed by native gel or analyzed by 10–
30% glycerol or 5–20% sucrose gradient sedimentation in
the presence of 10 mM magnesium. It has been shown that
monomers, dimers, and trimers were separated by sedimentation. Plotting the hypothetical molecular weight vs
the log of migration distance (the fractional number) in
gradient revealed a linear relationship.170 Trimers can be
further conﬁrmed by AFM imaging if necessary.
1971
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efﬁciency. The fact that the three inactive
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pRNAs are fully active when mixed together is not surprisTue, 27 Noving,
2007
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since
the number of pRNAs in the DNA-packaging
complex is a multiple of 2 (six copies), in addition to being
a multiple of three. The mechanism of dimer formation
by interlocking loop/loop interaction will be utilized to
construct chimeric pRNA dimers carrying receptor-binding
RNA aptamer and/or therapeutic RNA molecules.
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5.1.4. Construction of Hexamers

Guo

(A)

Recently, an “annealing approach” has been employed to
assemble hexamer (unpublished data).
5.2. HIV RNA Dimer

REVIEW

HIV dimerization occurs through loop–loop interactions
between the stem loops of two identical RNA molecules
(Fig. 5). The resultant “kissing complex” refolds into a
more stable complex known as an extended dimer. Still,
little is known about the transitional pathway due to difﬁculties involved in directly observing the intermediate
processes.171–173 Understanding this pathway could lead to
signiﬁcant improvements in the treatment of the disease
caused by the virus and the application of such RNA–RNA
interaction in nanotechnology.
5.3. TectoRNA

(B)
Delivered by Ingenta
to: (a)

RNA has been formed into “jigsaw puzzle”
pieces
known
Purdue
University
Libraries
for
the
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production of nanoscale fabrics with controllable
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tionality and geometry41 (Fig. 5). In contrast to traditional materials, where materials are selected, rather than
designed, for a given application, the next generation of
materials will allow for the a priori design of novel building blocks, programmed for assembly and synthesized
with particular needs in mind.

(b)

5.4. mRNA Dimerization in Drosophila Embryos
The multilization of mRNA is of considerable importance for the localization of ribonucleoprotein particles in
Drosophila embryos.176 177 Dimerization proceeds through
a two-step mechanism via a hand-in-arm interaction,
which includes a transition from the reversible initiation
complex into a very stable one.178 179 A series of different RNA fragments with the capacity to form a variety of
structures, including open dimers and closed dimers and
other multimers, were constructed.178–180 The initial open
dimer is converted into a stable closed dimer, perhaps due
to a kinetically-controlled mechanism.

6. APPLICATIONS OF RNA
NANOTECHNOLOGY IN MEDICINE
Nanotechnology has brought about an unprecedented variety of revolutionary approaches for the detection and
therapy of diseases. Due to their small size, nanoparticles
can readily interact with biomolecules either on the surface
or within cells. To take advantage of this, it is desirable
to develop multifunctional engineered, targeted complexes
capable of bypassing biological barriers to deliver multiple
therapeutic agents directly to speciﬁc cells or tissues. Due
to their easy access to many areas of the body, multivalent
nanoparticles could offer a wealth of innovative tools with
1972

Fig. 5. Model of HIV-1 RNA and TectoRNA structure. (A) HIV-1 RNA
secondary structure models. Model of the structural rearrangements in
the TAR hairpin. TAR dimerization induced by the nucleocapsid protein gives rise to a kissing-loop complex and an extended duplex. The
following sequences are marked: the central palindrome (red), extended
base-pairing (blue), and secondary parallel helix (green; gray dotted lines
in extended duplex). Adapted with permission from [216], E. S. Andersen
et al., J. Biol. Chem. 279, 22243 (2004). © 2004, American Society
for Biochemistry and Molecular Biology. (B) TectoRNAs employing two
loop-receptor motifs and their modes of assembly. (a) Two modes of
assembly used in this study. (b) Schematic of RNA assembly unit showing elements varied for this study. The tetraloop (L) is shown in red, the
tetraloop receptor (R) in green, the linker (or hinge) in blue and the insert
[comprising a helix and a second linker (or hinge)] in magenta (refer also
to the 2D and 3D models in Figs. 2 and 3). Adapted with permission
from [175], L. Jaeger et al., Nucleic Acids Res. 29, 455 (2001). © 2001,
Oxford University Press.

the potential to combine detection and therapy in ways
previously unimaginable.
RNA molecular therapy is widely understood to be one
of the most promising applications of modern biological
science.181–185 There are many molecules that could potentially be utilized for nanotechnology-based RNA therapy
such as small interfering RNA,65–67 186 ribozymes71 73 184
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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and anti-sense RNA68 69 which all show signiﬁcant potentials to down-regulate speciﬁc gene expression in cancerous or viral-infected cells.187 The successful application
of siRNAs and ribozymes for the treatment of cancer
and infectious diseases requires overcoming the following obstacles: (1) the difﬁculty of entering the cell due to
the size limit for membrane penetration; (2) degradation
by exonucleases within the cell; (3) trafﬁcking into the
appropriate cell compartment; and (4) correct folding of
the ribozymes or siRNA in the cell if fused to a carrier.
At this time, the development of a safe, efﬁcient, speciﬁc,
and nonpathogenic nanodevice for the delivery of multiple
therapeutic RNAs is highly desirable.

interactions can be reliably probed. A variety of types
of artiﬁcially produced antisense RNAs have been developed, and their applications for therapeutic purposes are
just beginning to be fully realized.
6.1.4. Aptamer75 98 99 195

J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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Aptamers are a family of RNA- or DNA-based oligonucleotides obtained by in vitro screening that bind to
selected targets, including proteins, organic compounds,
and nucleic acids.75 99 Their usefulness is found in their
ability to recognize the ligands through the formation of
binding pockets analogous to antigen–antibody interaction.
SELEX is the method which screens for the aptamers from
these randomized RNA pools. Starting with a library con6.1. Small RNA Molecule with
taining random RNA sequences with about 1014–17 variTherapeutic Potentials
eties of RNA molecules, in vitro binding, elution, and
188 189
reverse PCR ampliﬁcation techniques allow for the selec6.1.1. siRNA
tion of RNA molecules that efﬁciently bind to a speciﬁc
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interfere with gene expression through the cleavage
peptides, proteins, and receptors, have been
Tue, 27ofNovnucleotides,
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obtained.103 199–203
mRNA with homologous sequence by a protein/RNA complex named RISC (RNA-induced silencing complex). An
6.2. The Uniqueness of Therapeutic Nanoparticles
enzyme known as Dicer facilitates this process, which,
Derived from phi29 pRNA
as speciﬁed later in the gene therapy section of the
manuscript, has already exhibited signiﬁcant nanotechnoUntil recently, the use of small RNA in gene therapy was
logical applicability.46 47
signiﬁcantly hampered by the difﬁculties involved in producing a safe and efﬁcient system by which speciﬁc cells
6.1.2. Ribozyme70–73
could be targeted. Recently, phi29 pRNA has been used to
harbor small therapeutic RNA molecules46 47 for the delivRibozymes are RNA molecules that have the capability
ery to speciﬁc cancer cells (Fig. 6).
to catalyze chemical reactions. They have highly signifBy utilizing RNA nanotechnology, both therapeutic
icant potential for therapeutic purposes190 since they are
siRNA and a receptor-binding RNA aptamer was engicapable of regulating gene function by intercepting and
neered into individual pRNAs of phi29’s motor.46 47 The
cleaving messenger RNA or viral genomic RNA. Even
RNA building block harboring siRNA or other therapeuwithin the RNA subtype of ribozymes, there are signiftic molecules was fabricated subsequently into a trimer
icant structural and functional differences between difthrough the interaction of engineered right and left interferent molecules; hammerhead ribozymes191 and hairpin
locking RNA loops.43 48 132 166 167 The incubation of the
ribozymes192 are so named because of their appearance
protein-free nanoscale particles containing the receptorwhen visualized by microscope. These are both categobinding aptamer or other ligands resulted in the binding
rized as small ribozymes; larger ribozymes include introns
and co-entry of the trivalent therapeutic particles into cells,
and RNase P.193 194
subsequently modulating the apoptosis of cancer cells and
leukemia model lymphocytes in cell culture and animal
6.1.3. Antisense RNA68 69
trials. The use of such antigenicity-free 20–40 nm partiAntisense RNA molecules function through connecting
cles holds promise for the repeated long-term treatment
with particular target RNAs in order to regulate their funcof chronic diseases. Such protein-free 30 nm nanoparticles
tionality after transcription. They are called “antisense”
will allow for repeated long-term administration and avoid
because most often they are transcribed in a direction
problems of short retention time of small molecules less
opposite that of the target RNA from the same DNA tranthan 30 nm and the difﬁculty of delivery of particles larger
script. This allows for the production of a pair of tranthan 100 nm.
scripts that are complementary or nearly complementary.
In addition, since there are six chimeric pRNAs in the
hexamer, a polyvalent nanoparticle can be constructed by
The combination of these two types of RNA produces a
utilizing six available positions to carry molecules for cell
stable and easily detectable complex, and thus antisense
recognition, therapy, and detection (Fig. 12). Besides the
RNA provides a promising route by which RNA/RNA
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therapy. Therapeutic RNA molecules are typically vulnerable to RNase digestion. They can be protected by connecting both ends of the foreign RNA with both ends of the
pRNA. Circular permutation strategies were also applied
for this purpose.92 93 125 206 The feasibility of constructing
circularly permuted RNAs lies in the close proximity of
the native 5 and 3 ends.104 The feasibility of constructing
functional RNA that harbors actual ribozymes has been
recently demonstrated.20 The monomer pRNA carrying the
foreign daughter RNA molecule can also contain the same
designable right and left loops for the formation of dimers,
trimers, and hexamers. This section describes the construction of one subunit of the building block of the RNA
nano-particles.
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Recently, post-transcriptional gene-silencing and RNA
Fig. 6. Functional assay of chimeric pRNA/siRNA(GFP) by transinterference have been investigated extensively in a wide
fection. (A), (B), and (C) are ﬂuorescence microscopy images to
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for the formation of the silencing enzymatic complex
RNA. (a) No RNA; (b) Synthesized double-stranded siRNA(GFP);
required for cleavage of the target mRNAs.77 211 These
(c) Double-stranded siRNA(LacZ) control; (d) pRNA/siRNA(GFP); (e)
siRNAs speciﬁcally suppress the expression of a target
pRNA/siRNA(mutant); (f) pRNA vector alone (C) Comparison of the
performance of chimeric pRNA/siRNA(GFP) (a) and the conventional
mRNA with a sequence identical to the siRNA. Although
double-stranded -siRNA(GFP) (b) at the same molar concentration. Panel
the detailed mechanism of post-transcriptional gene silenc(c) is the control with no siRNA treatment. (D) Northern blot to examing and RNA interference remains to be elucidated, this
ine the effect of chimeric pRNA/siRNA(GFP) on GFP mRNA level after
powerful new technology for selective inhibition of spetransfection. Lanes 1 and 2 show the effects of two different constructs
ciﬁc gene expression employing siRNAs has shown great
of pRNA/siRNA(GFP). Lane 3 is the double-stranded siRNA and lane 4
is cells without RNA treatment. rRNA was used as loading control.
promise in the therapy of cancer and viral infections.64 67
Reprinted with permission from [46], S. Guo et al., Human Gene Therapy
Bacterial phage phi29 pRNA contains a double-stranded
16, 1097 (2005). © 2005, Mary Ann Liebert, Inc.
 
small RNA and folate reported, other materials such as
heavy metal, quantum dots, ﬂuorescent beads or radioisotopes can also be conjugated for the detection of cancer
signatures at different stages of development. The conjugation of endosome-disrupting chemicals could be used to
promote the release of internalized therapeutic reagent from
the endosome to improve therapeutic efﬁcacy. This polyvalent RNA complex can also potentially be used for treating chronic viral infections through targeting at the speciﬁc
virus-glycoproteins displayed on the infected cell surface.
It is well-established in the scientiﬁc community that
RNAs do not induce a detectable immune response except
when complexed with proteins.204 205 The use of RNA as
a delivery vehicle could avoid the problems of immune
response and the rejection of protein vectors after repeated
long-term drug administration for chronic diseases.
6.3. Construction of Chimeric pRNA Subunit
Harboring Therapeutic Moieties
An important task in constructing chimeric monomers is to
protect the delivered therapeutic molecule from exonuclease degradation, a problem commonly encountered in gene
1974

helical domain at 5 /3 end and an intermolecular binding
domain, which fold independently of each other. Complementary modiﬁcation studies have revealed that altering the primary sequences of any nucleotide of the
helical region does not affect pRNA structure and folding as long as the two strands are paired (Fig. 1).104
Extensive studies revealed that siRNA is a double-stranded
RNA helix.64 65 67 209 To test whether it is possible to
replace the helical region in pRNA with double-stranded
siRNA, a variety of chimeric pRNAs with different targets were constructed to carry siRNA connected to
nucleotides #29 and 91 of the pRNA (Fig. 1), resulting
in pRNA/siRNA(GFP), pRNA/siRNA(Luciferase), and
pRNA/siRNA(Survivin).
Chimeric pRNA/siRNA(GFP) was constructed and the
speciﬁc inhibition of GFP expression by this RNA building block was demonstrated in mRNA and protein level
(Fig. 6). pRNA/siRNA(Luciferase) was another building
block RNA proven to successfully inhibit target gene
expression (Fig. 7). Two chimeric pRNA/siRNA constructs
targeting either ﬁreﬂy luciferase or Renilla luciferase
were found to inhibit target luciferase gene expression
without showing non-speciﬁc inhibition to internal control luciferase gene expression. In addition, chimeric
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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Fig. 7. Functional assay of chimeric pRNA/siRNA targeting luciferase
by transfection. (A) Dual reporter luciferase assay showing the speciﬁc knockdown of ﬁreﬂy luciferase or renilla luciferase expression by
pRNA/siRNA(Fireﬂy) or pRNA/siRNA(Renilla), respectively in a dose
dependent manner. (B) Comparison of the activities of the conventional hairpin siRNA(Luciferase) and pRNA/siRNA(Luciferase). pRNA/
siRNA(mutant) with mutations in siRNA sequences was included as a
nonspeciﬁc control. Reprinted with permission from [46], S. Guo et al.,
Human Gene Therapy 16, 1097 (2005). © 2005, Mary Ann Liebert, Inc.

pRNA/siRNA exhibited equivalent or superior inhibitory
effects on target gene expression compared with chemically synthesized double-stranded siRNA or hairpin
siRNA (GFP) (Fig. 6). pRNA/siRNA(Survivin) and
pRNA/ribozyme(Survivin) targeting an anti-apoptosis factor survivin, which is necessary to down-regulate genes
involved in tumor development and progression, was
shown to suppress survivin expression, initiate apoptosis
and cell death (Fig. 8).
6.3.2. Harboring Hammerhead Ribozyme20
Connecting the pRNA 5 /3 ends with variable sequences
did not disturb its folding and function. These unique
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005

Fig. 8. Apoptosis and cell death induced by transfection of chimeric
pRNA harboring siRNA targeting survivin. (I) Breast cancer MCF-7 cells
were transfected with pRNA/siRNA(Survivin) and apoptosis was monitored using PI/annexin V double-labeling followed by ﬂow cytometry.
Cells at the lower right quadrant represent apoptotic cells. (II) Breast
cancer cells MDA-231 and prostate cancer cells PC-3 were transfected
with 20 pmol of pRNA/siRNA(Survivin) in 24-well plates and images
were taken in 24 hours after transfection. The mutant pRNA/siRNA was
transfected in parallel as a negative control. Reprinted with permission
from [46], S. Guo et al., Human Gene Therapy 16, 1097 (2005). © 2005,
Mary Ann Liebert, Inc.

features, which help prevent two common problems—
exonuclease degradation and misfolding in the cell, make
pRNA an ideal vector to carry therapeutic RNAs. A pRNAbased vector was designed to carry hammerhead ribozymes
that cleave the hepatitis B virus (HBV) polyA signal.
The chimeric HBV-targeting ribozyme was connected to
the pRNA 5 /3 ends as circularly permuted pRNA. Two
cis-cleaving ribozymes were used to ﬂank and process the
chimeric ribozyme. The hammerhead ribozyme including its two arms for HBV targeting was able to fold
correctly while escorted by the pRNA. The chimeric
ribozyme cleaved the polyA signal of HBV mRNA in vitro
almost completely. Cell culture studies showed that the
chimeric ribozyme was able to enhance the inhibition of
HBV replication when compared with the ribozyme not
escorted by pRNA, as demonstrated by Northern blot and
e-antigen assays. pRNA could also carry another hammerhead ribozyme to cleave other RNA substrate.
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6.3.3. Harboring Antisense RNA68 69

6.3.4. Harboring Receptor-Binding Aptamer

I.Assay for co-entry of 3 RNAs in trimer
CD4+ Cells
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Single CD4+ cell

(E)

(I)

(B)

(F)

(J)

FITC

(A)

Rhodamine

Antisense RNAs are single-stranded RNA molecules complementary to mRNA. Antisense RNA can inhibit gene
expression in the cell.68 69 This applies to the construction of chimeric RNA monomers carrying single-stranded
antisense RNA. All antisense RNA used to block gene
function are placed at the 3 -end of the pRNA.
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an attractive alternative since it avoids the induction of
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ends relocated to residues #71 and 75, respectively, of the
II. Control assay to differentiate entry from binding
original pRNA sequence. The 71/75 end is located in a
135
tightly-folded area to bury and protect the ends from
exonuclease degradation in vivo.20
6.3.5. Adding Drugs, Folate, or Other Chemical
Moieties or Groups to RNA
Some cancer cells overexpress the receptor for folate,
which has been shown to be a useful target for the speciﬁc delivery of drugs in cancer therapy.212 213 Other drugs
might be incorporated into the therapeutic complex to
enhance the therapeutic effect. Chemicals for image detection or endosomal disruption can also be connected to the
RNA complex. Therefore, it is desirable to have simple
and efﬁcient methods for the conjugation of such groups
to RNA. Such additions include labeling with pCp, DIG,
phosphate, as well as biotin, amine, sulfhydryl, and carboxyl groups, which are simple and efﬁcient groups for
conjugation. NHS can be used to covalently link particles
with a primary amine group. NH2 -group can be used to
link any particles with a COOH group with the help of
EDC, or with Cysteine or SH-group using a variety of
amine and sulfhydryl reactive heterobifunctional crosslinkers such as BMPS. Sulfhydryl-groups can be used to
link NH2 -groups via BMPS or with any common chemicals that contain maleimide. Maleimide can be used to
link covalently with any particles that contain SH-group.
In addition, NH2 /NH2 interaction can be achieved via commercially available heterobifunctional crosslinkers as well.
Folate receptors are over-expressed in various types
of tumors such as human nasopharyngeal epidermal
carcinoma but are generally absent in normal adult tissues.
The folate molecule, which binds to folate receptor with
1976

(M)

(N)

(O)

(P)

Fig. 9. Confocal microscopy showing the speciﬁc and simultaneous
delivery of three components to CD4 over-expressing cells. (I) Assay
for the binding of pRNA trimer containing pRNA(A-b )/aptamer(CD4),
pRNA(B-e )-FITC, and pRNA(E-a )-Rhodamine to CD4 over-expressing
T cells (A–D of left column, and I–L of right column) and CD4 negative
cells T cells (E–H of middle column). A, E, and I were imaged with an
FITC ﬁlter; whereas B, F, and J were viewed with a Rhodamine ﬁlter;
C, G, and K are overlays; and D, H, and L are DIC images. The right
column represents a close-up view of CD4 over-expressing cells. Arrows
point to the complexes that had entered the cell. (II) Section of confocal
microscopy images to differentiate between binding (M) and cell entry
(arrows in N and O) as well as negative control (P). Binding of FITClabeled pRNA trimer containing CD4-binding aptamer to lymphocytes
was shown as a circle and entry was shown as a green spot inside cell
(arrow in O). The red color in N is a positive entry control of transferrin
labeled with Texas red. Reprinted with permission from [47], A. Khaled
et al., Nano Lett. 5, 1797 (2005). © 2005, American Chemical Society.

high afﬁnity, was incorporated into the 5 end of RNA
by in vitro transcription using folate-AMP. Speciﬁc cell
binding of pRNA/folate dimer was demonstrated by incubating folate receptor positive KB cells with dimeric
pRNA which contains a folate labeled pRNA(A-b ) and a
[H3 ]-pRNA(B-a ). Then the nanoparticles containing both
folate-labeling and chimeric pRNA/siRNA were shown to
knockdown the ﬁreﬂy luciferase gene expression by a simple incubation process (Fig. 10). Furthermore, animal trials were performed to demonstrate speciﬁc suppression
of tumorigenicity of cancer cells by ex vivo delivery
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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Fig. 10. Speciﬁc delivery of chimeric pRNA/siRNA by folate-pRNA. (A) Flow cytometry analyses of the binding of folate-pRNA-FITC to KB cells.
Cells were incubated with folate-pRNA labeled with FITC (left panel). Cells in the middle panel were pre-incubated with free folate, which served
as a blocking agent to compete with folate-pRNA for binding to the receptor. Binding was also tested using folate-free pRNA labeled with FITC
(right panel) as a negative control. The percentages of FITC-positive cells are shown in the upper right quadrants. (B) Speciﬁc binding of folate-pRNA
dimer to KB cells. After incubation of cells with the [3 H]-folate-pRNA dimer in the presence (center column) or absence (left column) of free folate,
cells were isolated and subjected to scintillation counting. The right column is the [3 H]-dimer without folate labeling as a negative control. (C) In the
knockdown assay by incubation, folate-chimeric dimer complex containing pRNA(B-a )/folate and pRNA(A-b )/siRNA(ﬁreﬂy) was incubated with KB
cells for 3 hours to allow the binding and entry of RNA. The luciferase level was measured in the next day by the dual reporter system. The control
dimer was identical to the folate dimer except for its lack of folate labeling. Reprinted with permission from [46], S. Guo et al., Human Gene Therapy
16, 1097 (2005). © 2005, Mary Ann Liebert, Inc.

6.4. Assembly of Deliverable Dimeric, Trimeric
Therapeutic RNA Nano-Particles
RNA nano-particles containing two or three chimeric
RNA building blocks were constructed. Nano-particles
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005

carry multiple components, including molecules for speciﬁc cell recognition, image detection, and therapeutic
treatment. One subunit of the deliverable RNA complex
200

Tumor Volume (mm3)

of the nano-particle containing both folate labeling and
chimeric pRNA/siRNA against survivin. The potential of
this RNA complex to suppress tumor formation was tested
in athymic nude mice. Human nasopharyngeal epidermal
carcinoma KB cells were incubated with a chimeric RNA
complex with or without folate before being introduced
into the nude mice by axilla injection. The mice receiving
only cancer cells developed tumors within 3 weeks, while
the group of mice that received cancer cells pre-treated
with the pRNA complex containing both folate-pRNA and
pRNA/siRNA(Survivin) did not develop tumors (Fig. 11).
The inhibition of tumor formation is speciﬁc since the
control RNA complex without folate or the RNA complex containing mutations in survivin siRNA did not affect
tumor development in other mice groups.
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Fig. 11. Animal trials for cancer therapy using the fabricated RNA
nanoparticles. (A) Injection without the pRNA/siRNA chimera (No
RNA); (B) Treatment with RNA chimera containing folate-pRNA and
siRNA(Survivin); (C) Treatment with RNA chimera containing folatepRNA and siRNA(Survivin) with mutations in the siRNA sequence;
(D) Treatment with pRNA-siRNA chimera that does not contain a folate
at its 5 end. Reprinted with permission from [47], A. Khaled et al., Nano
Lett. 5, 1797 (2005). © 2005, American Chemical Society.
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the trimer of chimeric pRNA harboring receptor-binding
RNA aptamer and/or therapeutic siRNA (Fig. 9). Individual chimeric pRNA building block was engineered to
carry one daughter RNA molecule such as siRNA or
receptor-binding aptamer. Each building block was intentionally designed to have speciﬁc right or left loops, such
as A-b (right–left), to interact with other building block.
The appropriate folding of pRNA and their competency
in forming trimers were conﬁrmed. Mixing of individual
chimeric pRNAs with counterpart partners with appropriate interlocking loops resulted in the efﬁcient formation
of the desired trimer, as documented by gel electrophoresis, AFM imaging, and sucrose gradient sedimentation.
This suggests that RNA trimers were generated from the
monomeric building block despite the replacement of the
5 /3 helix with ds-siRNA or the connection of the 5 /3
end to a CD4-binding aptamer.
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would therefore be six positions available to carry
foreign
for
targeting, therapy, and detection, as shown in the ﬁgure. Reprinted with
cle for the concurrently delivery of multiple therapeupermission from [46], S. Guo et al., Human Gene Therapy 16, 1097
tic particles, a trimeric pRNA/aptamer(CD4) complex was
(2005). © 2005, Mary Ann Liebert, Inc.
(dimer, trimer) was modiﬁed to carry an RNA aptamer
or other receptor binding ligands that bind a speciﬁc cellsurface receptor, thereby inducing receptor-mediated endocytosis. The second subunit carried reporting molecules
such as ﬂuorescent beads. The third subunit was altered to
carry therapeutic siRNA, ribozyme RNAs, antisense RNA,
or other drugs to be delivered.47
6.5. Sequence Requirement of the Hand-in-Hand
Loops in Chimeric Trimer Formation
Bases 45–48 and 82–85 of wild type pRNA in the leftand right-hand loops, respectively, were found to engage
in pRNA/pRNA interactions.131 166 Without considering
tertiary interaction, in some cases only two G/C pairs
between the interacting loops could allow the formation of pRNA multimers. When all four nucleotides were
paired, at least one G/C pair was required. The maximum number of base pairings between the two loops to
allow optimal polymer formation was ﬁve. The minimum
number of nucleotides needed for pRNA/pRNA interaction
in the right and left loop was ﬁve and three, respectively.
Our results suggest that a 75-nucleotide RNA segment,
nucleotide 23–97, is a self-folded independent domain
involved in RNA/RNA interaction in pRNA trimer formation, while nucleotide 1–22 and 98–120 were dispensable
for RNA/RNA interaction.
The mechanism of pRNA trimer formation by interlocking loop/loop interaction was utilized for the fabrication of
1978

constructed and additional components were added to it in
order to demonstrate the successful binding and entry of
the multivalent complex into cells. In this trimer, one of the
subunits was the pRNA(A-b ) chimera harboring the CD4binding aptamer. The other two subunits carry the FITC
(green) molecule and Rhodamine (orange label) molecule,
respectively. To test the binding and entry of the trimer,
a confocus section approach was attempted with the use
of difference ﬁlters (Fig. 9). Binding of the trimer to the
cells was demonstrated by the ﬁnding that ﬂuorescence
color appeared on the cell surface as a circle, which is
one layer of the cell from the confocal microscope. Entry
of the trimer into the cell via CD4-mediated endocytosis was demonstrated by the appearance of a ﬂuorescence
spot within the cell (Figs. 9A, B, K, and L). Such binding and entry was speciﬁc as long as CD4 was present,
since no ﬂuorescence was observed on CD4-negative cells
(Fig. 9-I, lower panel). The appearance of both types of
ﬂuorescence on the cell surface suggests that pRNA(B-c )
and pRNA(C-a ) had been conjugated onto CD4-binding
aptamer A-b , which had no ﬂuorescence label but had
the capacity for CD4 binding. Figures 9K–L, when compared with Texas Red-labeled transferrin as the positive
control for entry (Fig. 9J), further illustrates the success
in entry. The similarity and overlap of the FITC image
with the rhodamine image in Figures 9K–L strongly indicates that the FITC-labeled pRNA(B-c ) had combined
with the rhodamine-labeled pRNA(C-a ) and been codelivered to the cell. All of these results indicate that RNA
trimers can serve for the delivery of multiple therapeutic
components.
J. Nanosci. Nanotechnol. 5, 1964–1982, 2005
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